These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15319664)

  • 1. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
    Piliero PJ
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New nucleoside/nucleotide backbone options: a review of recent studies.
    Ruane PJ; DeJesus E
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance issues with new nucleoside/nucleotide backbone options.
    Wainberg MA; Turner D
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S36-43. PubMed ID: 15319668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
    Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
    Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.
    Molina JM; Cox SL
    Drugs Today (Barc); 2005 Apr; 41(4):241-52. PubMed ID: 16034488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing.
    Back DJ; Burger DM; Flexner CW; Gerber JG
    J Acquir Immune Defic Syndr; 2005 Aug; 39 Suppl 1():S1-23, quiz S24-25. PubMed ID: 15990598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB; Stone EA; Piacenti FJ
    Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in antiretroviral therapy.
    Young B
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S13-20. PubMed ID: 15319665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance.
    Bertoletti N; Chan AH; Schinazi RF; Anderson KS
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33096918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ideal nucleoside/nucleotide backbone.
    Gallant JE
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S44-51. PubMed ID: 15319669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.
    Hammer SM
    Top HIV Med; 2006; 14(4):140-3. PubMed ID: 17114828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging anti-HIV drugs.
    De Clercq E
    Expert Opin Emerg Drugs; 2005 May; 10(2):241-73. PubMed ID: 15934866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
    Hukezalie KR; Thumati NR; Côté HC; Wong JM
    PLoS One; 2012; 7(11):e47505. PubMed ID: 23166583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
    Holec AD; Mandal S; Prathipati PK; Destache CJ
    Curr HIV Res; 2017; 15(6):411-421. PubMed ID: 29165087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.